Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03520959 Terminated - Cancer Clinical Trials

Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma

Start date: September 18, 2018
Phase: Phase 3
Study type: Interventional

To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.

NCT ID: NCT03351231 Terminated - Cancer Clinical Trials

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Start date: November 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

NCT ID: NCT03138408 Terminated - Cancer Clinical Trials

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Start date: June 14, 2017
Phase: Phase 1
Study type: Interventional

This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts.

NCT ID: NCT02973399 Terminated - Cancer Clinical Trials

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Start date: February 7, 2017
Phase: Phase 1
Study type: Interventional

SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical response in subjects who have residual disease, but have not progressed on ibrutinib after 18 months of monotherapy, and/or prevents or delays disease progression of subjects with CLL.

NCT ID: NCT02926209 Terminated - Cancer Clinical Trials

Post Market Evaluation of Aer-O-Scope Visualization

Start date: February 21, 2017
Phase: N/A
Study type: Interventional

This will be a prospective multi-center, multi-national comparative non-blinded clinical investigation. Each subject will undergo back-to-back tandem colonoscopies with the Aer-O-Scope Colonoscope System and a conventional colonoscope since this is a tandem colonoscopy study, each subject will serve as their own control. The 1st procedure will be randomized, half to Aer-O-Scope Colonoscope System and half to conventional colonoscope. The same investigator will perform both procedures on each subject. All pathologies found will be either removed or tattooed. Unmarked pathologies found on second pass will represent those missed during the 1st pass, thus making the subject and the control one and the same. Tattooed pathologies that can be removed endoscopically will be removed in an additional colonoscopy. This may occur if a large polyp cannot be removed for any reason with the Aer-O-Scope, but can be removed with conventional colonoscopy.

NCT ID: NCT02866851 Terminated - Cancer Clinical Trials

Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy

Start date: September 8, 2015
Phase: N/A
Study type: Interventional

Patients should receive a chemotherapy regimen with an overall risk of febrile neutropenia ≥ 20%. The use of the web-application their will be proposed . They will be informed of the risk of neutropenia, fever and bleeding which may occur beyond the fifth day of each chemotherapy cycle (to eliminate fevers related to treatment). The temperature measurement is performed at home by an infrared forehead thermometer provided as part of the study, in a systematic manner once daily at the same time of day and in case of unexplained fatigue or chills. Before any fever reported to the physician via the web-application (alert), a questionnaire will be completed by the patient to the search for gravity criteria to assess his condition at home. The patient will be hospitalized immediately if it shows signs of severity in order to document the infection and provide intravenous antibiotics adapted to the clinical condition; in the absence of these signs, the patient will make a count to the nearest lab and will receive oral antibiotics if indicated. The subsequent strategy will be defined by the web-application algorithm to optimize the care of patients. The ability to use a web-application could allow early detection of complications of post-chemotherapy haematological toxicity and offer a taking over guided by a decision-making algorithm managed by the physician. The aim is to favour the taking over at home.

NCT ID: NCT02860481 Terminated - Cancer Clinical Trials

FSH-R : Diagnostic Application for Localized Tumors in Cancerology

Start date: November 2013
Phase: N/A
Study type: Interventional

FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the diagnosis of cancer. A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will include n=10 patients per histological type except for breast cancer (n=50). 100 patients are expected in this cohort. A second cohort will explore the more promising histological type (if any) in term of incidence of detection. 100 patients are expected for this second cohort.

NCT ID: NCT02839889 Terminated - Pain Clinical Trials

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of a two week randomized double blind period followed by a two week open-label period.

NCT ID: NCT02785341 Terminated - Cancer Clinical Trials

Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact

Start date: May 2015
Phase: N/A
Study type: Interventional

Although treatments significantly increase the life expectancy of cancer patients, their quality of life is more or less reduced. The development of supportive care, such as physical activity, is one of the tools that should be promoted to maintain quality of life and reduce treatment side effects, including fatigue. This study was developed to understand the different biopsychosocial effects of a physical activity program carried out with patients suffering from various types of cancers, and to facilitate and improve the implementation of this type of activity in health care facilities. Study randomized, controlled, cross-over intervention evaluating a 12-week supervised and adapted physical activity program. Participants were assigned to one of two groups: Group A which first follows a 12-week physical activity program, then undergoes usual care for 12 additional weeks, or Group B, which continues usual care for 12 weeks (control group) and then starts the physical activity program for 12 additional weeks. Quality of life (with questionnaires for 2 groups) , well-being, fatigue, physical capacity, leptin concentration, goal setting and level of physical activity are evaluated during this protocol. By understanding the multidimensional effects of a physical activity program for various cancer types, depending on the time of proposing the program, by evaluating the correlations among all these variables, and by evaluating long-term effects, the IPCAPA study contributes to identifying the physical activity program which will be effective, viable and feasible for all patients undergoing chemotherapy, whatever the type of cancer.

NCT ID: NCT02722109 Terminated - Cancer Clinical Trials

Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy

Start date: August 2016
Phase: N/A
Study type: Observational

Researchers want to compare proton stopping ratios, used for proton beam therapy planning, calculated based on single energy CT and dual energy CT images; with the intension of improve upon the proton range determination.